From: Third-line therapy for chronic myeloid leukemia: current status and future directions
Drug/trial | Trial number/phase | Goals | Primary endpoint(s) |
---|---|---|---|
NCT04126681/phase II | To evaluate the efficacy of HQP1351 in patients with CML-CP who are resistant and/or intolerant to 1G and 2GTKIs | EFS | |
NCT03883087/phase II | To evaluate the efficacy of HQP1351 in patients with CML-CP and a T315I mutation | MCyR | |
PF-114 (BCR-ABL1 Inhibitor) [72] | NCT02885766/phase I/II | To evaluate tolerability, safety, pharmacokinetics, and preliminary efficacy of PF-114 in patients with Ph + CML who are resistant to 2GTKIs or have the T315I mutation | DLTs MTD |
K0706 (BCR-ABL1 Inhibitor) [75] | NCT02629692/phase I/II | To determine safety, tolerability, pharmacokinetics, and activity of K0706 in patients with CML or Ph + ALL | MTD TEAEs MCyR or partial cytogenetic response (CML-CP) CHR (CML-AP/BC) |
NCT03106779/phase III | To compare the efficacy of asciminib with that of bosutinib in patients with CML-CP in the 3L + setting | MMR at 24 weeks | |
NCT02081378/phase I | A dose-finding study of asciminib alone or in combination with nilotinib, imatinib, or dasatinib in patients with CML and Ph + ALL who are relapsed/refractory to or are intolerant of TKIs | MTD and/or RDE DLTs |